This session recording is from Sept. 18, 2025
Rare Advocacy Exchange Session 7:
Getting A Precise Diagnosis is Critical for Adults & Children
Overview
This session explored why a timely and accurate molecular diagnosis is transformative for rare disease patients and families. It highlighted how genetic testing is reshaping research, treatment, and family care. A precise genetic diagnosis is not just a label: it is a gateway to clarity, community, and care. The panel emphasized both the breakthroughs (AI platforms, expanding guidelines, gene-based therapies) and the barriers (misconceptions, inequities, lack of clinician education, insurer resistance) in shortening the diagnostic odyssey.
Opening Remarks
Cody Barnett, Patient Advocacy – United States, Canada, & Latin America at Illumina.
Moderated by
Effie Parks (Once Upon a Gene podcast, CTNNB1 mom)
Panelists
Lukas Lange (CEO, Probably Genetic),
Dr. Pranav Garimella (American Kidney Fund),
Dr. Michael Kruer (Phoenix Children’s/University of Arizona)
Top Takeaways
- Diagnosis = Lifeline — Beyond naming a disease, a genetic diagnosis informs treatment options, clinical trial eligibility, prognosis, and family planning.
- Umbrella labels are not enough. Terms like “chronic kidney disease,” “cerebral palsy,” or “autism” are descriptive, not explanatory. Digging into the why is crucial.
- AI is reshaping access. Platforms like Probably Genetic use patient-driven data, AI, and telehealth to close diagnostic gaps.
- Data privacy matters. Patient consent, opt-in recontact, and de-identified data sharing build trust and enable long-term value.
- Equity gaps persist. Communities of color (e.g., APOL1-linked kidney disease in Black populations) are disproportionately impacted but under-tested.
- Telemedicine + counseling = access. Genetic tests alone aren’t enough; patients need interpretation, counseling, and guidance.
- Patient advocates drive change. Families often educate their own providers, spread awareness, and accelerate adoption of testing.
- Reclassification of variants (VUS) is ongoing. Many uncertainties today may be clarified tomorrow; repeat or updated testing can bring answers.
- Cross-pollination between umbrella and rare groups strengthens research infrastructure, natural history studies, and trial readiness.
- The future is near. With AI and large-scale initiatives (e.g., NIH’s RAPID program), the panel envisioned eliminating the “diagnostic odyssey” within five years.
Considerations for Advocates & Community
- Equip families to ask for genetic testing when confronted with ambiguous diagnoses.
- Educate primary care providers and specialists about when and how to order testing.
- Advocate for coverage of WES/WGS as first-tier diagnostics.
- Build bridges between rare condition-specific groups and umbrella communities (autism, CP, kidney disease) to leverage shared tools and outcome measures.
- Push for equitable access—testing programs must reach underserved, rural, and minority communities.
- Encourage clinicians to revisit old tests, re-check VUS classifications, and stay current with evolving guidelines.
Useful Resources
- Quick Guide to Genetic Diagnosis
- www.probablygenetic.com (patient-initiated genetic testing with telemedicine oversight).
- www.kidneyfund.org
- Once Upon a Gene effieparks.com/podcast
- startgenetic.org
- KDIGO Guidelines: Genetic Kidney Disease
- ASN Genetic Testing Toolkit (from the American Society of Nephrology)
- AAP Clinical Report: Whole exome/genome sequencing as first-tier for unexplained developmental delay.
- Unknown Causes of Kidney Disease project
- Rare Kidney Disease Action Network
- Cerebral Palsy Research Network (umbrella collaboration with rare subtypes).
- Genome Medical (telehealth-based genetic counseling/testing service).
- Free/Low cost programs through Natera, Alport Syndrome Foundation, and Invitae Sponsored Testing programs
- A new way to access genetic testing – GeneDx®

Questions Posed & Key Answers
• Can Primary Care Providers order WGS?
→ Yes, but comfort and reimbursement vary. Telehealth services like Genome Medical may help.
• What about re-testing after 10 years?
→ Yes, technology and classification have advanced significantly.
• How to handle Variant of Uncertain Significance ( VUS ) results?
→ Revisit results regularly; ~75% of VUSs are eventually reclassified as benign. AI and phenotype tools are helping refine classifications.
• How can we expand access in communities of color?
→ Patient voices + advocacy education are key; providers must recognize genetic predispositions like APOL1.
Great Quotes & One-Liners
- “A diagnosis isn’t the end. It’s the beginning.” – Cody Barnett
- “Chronic kidney disease is like saying you have a fever. It’s not a diagnosis—it’s a symptom.” – Dr. Garimella
- “Umbrella (diagnosis) labels help, but we must always ask: why?” – Dr. Kruer
- “AI can be the Harry Potter sorting hat—matching families to the right diagnosis and community.” – Lukas
- “If you got a genetic test done, tell your doctor. They might test the next patient—and that changes everything.” – Lukas
- “You won’t find a patient with breast cancer today who hasn’t had genetic testing. Rare disease needs to catch up.” – Dr. Garimella
- “Five years from now, I want to see the diagnostic odyssey gone.” – Lukas
- “We may only have treatments for 5% of rare diseases, but diagnosis builds the case for the 95% still waiting.” – Panel consensus


Stay Connected
Sign up for updates straight to your inbox.
